ORGANON (OGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for OGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| OGN | Executive Chair of the Board; Chairman of the Board | 68 | ["Executive Chair of Organon & Co.","Former Chief Executive Officer of Humacyte, Inc.","Former EVP of Schering-Plough","Current Chairman of Solventum Corporation","Director of Texas Instruments Inc.","Chief Executive Officer of Humacyte, Inc. (2010-2018)","Chairman of Humacyte's board (2013-2019)","Executive Vice President of Schering-Plough Corporation (2003-2009)","President of Schering-Plough’s global pharmaceutical business (2003-2009)","President of Pharmacia Corporation's global pharmaceutical business (1997-2003)","Chairman of the board of directors of Solventum Corporation"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| SOLV | Chair of the Board; Chair of the board | 68 | ["Former Chief Executive Officer, Humacyte, Inc.", "30 years of experience in leadership roles and member of multiple boards at healthcare companies", "Pharmaceutical and biotech executive experience including as CEO of a regenerative medicine company", "Significant experience as a seasoned executive and audit committee member", "Service on the boards and senior executive roles at global healthcare companies", "Deep experience in guiding companies undergoing significant transitions, including recently spun-off companies, as well as in M&A transactions", "Deep experience at head of drug and biotech development companies; Responsible for significant capital and R&D investments", "Management responsibility of a large multinational company operating in a regulated industry", "Roles including oversight of sales plans, marketing and brand for large global companies", "Significant experience as chair of board at multiple public and private companies with oversight over risk", "Notable compensation committee expertise"] | ["TC", "STQC", "Talent", "Science, Technology and Quality"] | 2026 |
| TXN | Director; Former chairman and chief executive officer of Humacyte, Inc. | 66 | ["Multinational experience","Executive leadership (public or private)","Technology, research and development","Financial acumen","Sustainability","Management responsibility of a large multinational company operating in a regulated industry","Responsibility for significant capital and R&D investments"] | ["AuditCommittee"] | 2024 |
| CAH | Chair of the Human Resources and Compensation Committee | [] | ["Human Resources and Compensation Committee", "Governance and Sustainability Committee"] | 2023 |
Biography sourced from the proxy statement filing.
Ms. Cox serves as Executive Chair of Organon s Board. Ms. Cox served as the Chief Executive Officer of Humacyte, Inc., a then privately-held regenerative medicine company, between 2010 and 2018; in addition, she served as Chairman of the company s board between 2013 and 2019, and she remained a member of its board until 2021, prior to its public offering. Ms. Cox served as Executive Vice President of Schering-Plough Corporation and President of Schering-Plough s global pharmaceutical business between 2003 and 2009, when Schering-Plough merged with Merck. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation s global pharmaceutical business from 1997 until its merger with Pfizer Inc. in 2003. She also currently serves as Chairman of the board of directors of Solventum Corporation and as a director of Texas Instruments Inc. She served as chairman of the boards of directors of Cartesian Therapeutics, Inc. (from 2023 until 2025), Selecta Biosciences, Inc. (from 2019 until its merger with Cartesian Therapeutics, Inc. in 2023), and Array BioPharma Inc. (from 2018 until its acquisition by Pfizer Inc. in 2019). She also served on the board of directors of Celgene Corporation from 2009 until its acquisition by Bristol-Myers Squibb Company in 2019, on the board of directors of Cardinal Health Inc. between 2009 and 2023, and as Chairman of the board of directors of electroCore, Inc. between 2018 and 2020. Ms. Cox is a graduate of the Massachusetts College of Pharmacy. Ms. Cox brings to the Board her prior management experience as an executive of a large pharmaceutical company, as well as extensive leadership and corporate governance experience with other large and small biopharma companies.